Lactobacillus casei DG

DIETARY_SUPPLEMENT3 trials

Sponsors

SOFAR S.p.A., University of Padova

Conditions

Ileal PouchIrritable Bowel SyndromePouchitisUlcerative Colitis

Phase 4

Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study

CompletedNCT02077699

SOFAR S.p.A.Irritable Bowel Syndrome

Start: 2012-03-31End: 2014-06-30Updated: 2014-12-02

Unknown Phase

Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study

CompletedNCT02371499

SOFAR S.p.A.Irritable Bowel Syndrome

Start: 2014-12-31End: 2015-11-30Updated: 2016-02-02

Microbiota and Immune microEnvironment in Pouchitis

University of PadovaIleal Pouch, Pouchitis, Ulcerative Colitis

Start: 2016-10-31End: 2019-04-30Target: 32Updated: 2017-05-02

Related Papers

Oral administration of <i>Lactobacillus casei</i> DG® after ileostomy closure in restorative proctocolectomy: a randomized placebo-controlled trial (microbiota and immune microenvironment in pouchitis -MEP1)

Gut Microbes2024-11-014 citations

Effect of <i>Lactobacillus paracasei</i> CNCM I‐1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

United European Gastroenterology Journal2017-10-09108 citations